Skip to main content
    O

    Organogenesis Holdings Inc (ORGO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.80
    -0.01 (-0.86%)

    Market Cap: $105.15M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organogenesis Holdings Inc (ORGO) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Organogenesis Holdings (ORGO) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Organogenesis Holdings reported EPS of -$0.25, below the -$0.17 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    61%(19/31)
    Avg Surprise
    +47.36%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.13
    Range-$0.15 - -$0.12
    4 analysts
    Revenue Consensus
    $62.63M
    Range$56.74M - $68.14M
    4 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.14
    Range-$0.14 - -$0.14
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08-75.0%
    60d ago-$0.08-75.0%
    30d ago-$0.08-75.0%
    7d ago-$0.08-75.0%
    Current-$0.14
    Revenue Consensus
    $52.35M
    Range$48.90M - $55.80M
    2 analysts

    Next Report

    ORGO has an expected report date of Feb 24, 2027.

    ORGO Earnings Call

    The latest ORGO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, ORGO beat 19, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $45.46M, down 69.9% from $150.86M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.17-$0.17 - -$0.17-47.06%Miss-238.9%10 up, 1 downNov 5, 2026$45.46M
    Jun 30, 2026-$0.71-$0.35-$0.40 - -$0.30-102.86%MissN/A20 up, 1 downAug 6, 2026$43.76M
    Mar 31, 2026-$0.34-$0.29-$0.29 - -$0.29-17.24%MissN/A10 up, 1 downMay 7, 2026$37.23M
    Dec 31, 2025$0.31$0.22N/A+43.72%Beat+368.3%11 up, 0 downFeb 26, 2026$225.61M
    Sep 30, 2025$0.18$0.07$0.07 - $0.07+157.14%Beat+80.0%10 up, 1 downNov 6, 2025$150.86M
    Jun 30, 2025-$0.09-$0.01-$0.01 - -$0.01-800.00%Miss-325.0%10 up, 0 downAug 7, 2025$101.00M
    Mar 31, 2025-$0.11-$0.03-$0.03 - -$0.03-266.67%MissN/A10 up, 0 downMay 8, 2025$86.69M
    Dec 31, 2024$0.07$0.02$0.02 - $0.02+231.00%BeatN/A10 up, 1 downFeb 27, 2025$126.66M
    Sep 30, 2024$0.10$0.02N/A+400.00%Beat+150.0%40 up, 0 downNov 12, 2024$115.18M
    Jun 30, 2024$0.04$0.02N/A+100.00%Beat-20.0%40 up, 0 downAug 8, 2024$130.23M
    Mar 31, 2024-$0.01-$0.03-$0.04 - -$0.01+66.67%BeatN/A30 up, 0 downMay 9, 2024$109.98M
    Dec 31, 2023$0.00$0.01-$0.01 - $0.02-143.00%Miss-107.2%30 up, 0 downFeb 29, 2024$99.65M
    Sep 30, 2023$0.04$0.01$0.00 - $0.01+300.00%Beat0.0%20 up, 0 downNov 9, 2023$108.53M
    Jun 30, 2023$0.05$0.04N/A+25.00%Beat-28.6%20 up, 0 downAug 9, 2023$117.32M
    Mar 31, 2023-$0.01-$0.02-$0.02 - -$0.02+50.00%Beat-209.9%10 up, 0 downMay 10, 2023$107.64M
    Dec 31, 2022$0.06$0.05$0.05 - $0.05+20.00%Beat-84.6%10 up, 0 downMar 1, 2023$115.52M
    Sep 30, 2022$0.04$0.07N/A-42.86%Miss-66.7%20 up, 0 downNov 9, 2022$116.86M
    Jun 30, 2022$0.07$0.08N/A-12.50%Miss-50.0%N/A0 up, 0 downAug 9, 2022$121.40M
    Mar 31, 2022$0.01$0.06$0.02 - $0.08-84.83%Miss-88.6%30 up, 0 downMay 10, 2022$97.12M
    Dec 31, 2021$0.39$0.08$0.07 - $0.09+387.50%Beat+160.0%30 up, 0 downMar 1, 2022$127.86M
    Sep 30, 2021$0.12$0.06$0.06 - $0.06+100.00%Beat-36.8%3N/ANov 9, 2021$113.75M
    Jun 30, 2021$0.14$0.06$0.06 - $0.07+133.33%BeatN/A3N/AAug 9, 2021$123.20M
    Mar 31, 2021$0.08-$0.02-$0.07 - $0.01+500.00%BeatN/A3N/AMay 10, 2021$102.55M
    Dec 31, 2020$0.15$0.14$0.10 - $0.17+7.14%BeatN/A3N/AMar 16, 2021$106.81M
    Sep 30, 2020$0.19-$0.07-$0.11 - -$0.06+371.43%BeatN/A4N/ANov 9, 2020$100.80M
    Jun 30, 2020-$0.05-$0.26-$0.30 - -$0.12+80.77%BeatN/A4N/AAug 10, 2020$68.96M
    Mar 31, 2020-$0.16-$0.13-$0.17 - -$0.11-23.08%MissN/A4N/AMay 11, 2020$61.73M
    Dec 31, 2019-$0.04-$0.09-$0.10 - -$0.08+55.56%BeatN/A4N/AMar 9, 2020$74.64M
    Sep 30, 2019-$0.12-$0.12-$0.13 - -$0.120.00%In line-124.0%3N/ANov 12, 2019$64.27M
    Jun 30, 2019-$0.11-$0.13-$0.13 - -$0.11+15.38%Beat-375.0%3N/AAug 9, 2019$64.95M
    Mar 31, 2019-$0.15-$0.11-$0.13 - -$0.09-36.36%MissN/A4N/AMay 10, 2019$57.12M
    Dec 31, 2018-$0.12N/AN/AN/AN/AN/AN/AN/AMar 18, 2019$63.60M
    Sep 30, 2018$0.50N/AN/AN/AN/AN/AN/AN/ANov 9, 2018$50.77M
    Jun 30, 2018$0.04N/AN/AN/AN/AN/AN/AN/AAug 7, 2018$43.55M
    Mar 31, 2018-$0.01N/AN/AN/AN/A-150.0%N/AN/AMay 10, 2018$35.53M
    Dec 31, 2017-$0.13N/AN/AN/AN/AN/AN/AN/AMar 14, 2018$198.51M
    Sep 30, 2017-$0.30N/AN/AN/AN/AN/AN/AN/ANov 14, 2017N/A
    Jun 30, 2017-$0.04N/AN/AN/AN/AN/AN/AN/AAug 11, 2017N/A
    Mar 31, 2017$0.02N/AN/AN/AN/AN/AN/AN/AMay 12, 2017N/A
    Dec 31, 2016-$0.02N/AN/AN/AN/AN/AN/AN/AMar 28, 2017$61084
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.29, up 47.8% from the year before. It was -$0.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.29+47.8%
    Dec 31, 2024$0.20+159.2%
    Dec 31, 2023$0.08-57.7%
    Dec 31, 2022$0.18-75.5%
    Dec 31, 2021$0.73+461.5%
    Dec 31, 2020$0.13N/A
    Dec 31, 2019-$0.42-202.4%
    Dec 31, 2018$0.41N/A
    Dec 31, 2017-$0.45N/A
    Dec 31, 2016-$0.02N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,0365
    2026Q2Jun 30, 20264,1325
    2026Q1Mar 31, 20263,4574
    2025Q4Dec 31, 20253,2894
    2025Q3Sep 30, 20253,2175
    2025Q2Jun 30, 20253,5935
    2025Q1Mar 31, 20255,2576
    2024Q4Dec 31, 20244,1906

    2026Q3 Earnings Call

    Opening remarks

    Gary Gillheeney Sr. President, CEO, and Chair of the Board Thank you, operator, and welcome everyone to Organogenesis Holdings' third quarter 2026 earnings conference call. I am joined on the call today by Dave Francisco, our Chief Financial Officer. Let me start with a brief agenda of what we will cover during our prepared remarks. I will begin with a brief review of our results and key developments in the third quarter and in recent months. Dave will then provide you with an in-depth review of our third quarter financial results, our balance sheet and financial condition at quarter end, as well as our financial outlook for 2026, which we updated in our press release this afternoon. I will then provide you some closing comments before we open up the call for your questions. Beginning with a review of our results and key developments in Q3, our revenue results reflect the significant contraction and slow pace of recovery in the skin substitute market following the withdrawal of the LCD coverage policies for skin substitutes and CMS's published comments regarding discarded product in December of 2025. On balance, we were encouraged to see the operating environment improve from what we experienced during the second quarter, particularly as it relates to improving clinician confusion. Although net product revenue declined 70% year-over-year in the third quarter, our net product revenue increased 6% quarter-over-quarter in Q3. As a leader in the industry, we leveraged our most comprehensive portfolio across multiple FDA classifications, specifically the only biologic PMA-approved product, Apligraf, to enhance our market share position with an increase in volume on a quarter-over-quarter basis, outperforming the declines that have been reported across the industry. As discussed on our second quarter conference call, the competitive landscape has changed dramatically in the months following CMS's sweeping changes to payment policy. Distributor-driven competitors, high-priced amniotic players, and companies engaged in fraudulent practices have been substantially reduced. Many of the remaining players are diversifying away from wound care or exiting the category altogether. In this new market, customers are deciding which products and which partners they can trust, and they are deciding based on efficacy, outcomes, and evidence. That is the foundation Organogenesis was built on and the primary driver of the continued growth in market share we are achieving this year. These gains are broad-based, with Apligraf, PuraPly AM, Affinity, and NuShield all demonstrating meaningful improvement. That breadth tells us that customers are placing their confidence in our portfolio, not just a single product. We are also treating more patients, and utilization of our skin substitutes is increasing. Our team's commitment to our customers and their patients is paying dividends.

    Frequently Asked Questions About ORGO

    When is Organogenesis Holdings's next earnings date?

    Organogenesis Holdings's next earnings report is expected for Feb 24, 2027.

    Did ORGO beat earnings estimates last quarter?

    No. Organogenesis Holdings reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.17 estimate by 47.06%.

    What EPS do analysts expect from ORGO next quarter?

    The consensus EPS estimate for Organogenesis Holdings for the quarter ending Dec 31, 2026 is -$0.13 from 4 analysts, with estimates from -$0.15 to -$0.12.

    How often does ORGO beat earnings estimates?

    Organogenesis Holdings beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -100.25%.